Date published: 2026-7-27

1-800-457-3801

SCBT Portrait Logo
Seach Input

1700023E05Rik Inhibitors

1700023E05Rik Inhibitors are designed based on the intricate understanding of the protein's structure, function, and the molecular mechanisms by which it interacts with other cellular components. These inhibitors are typically small molecules that have been optimized through various chemical synthesis and modification processes to achieve high affinity and specificity towards the 1700023E05Rik protein. The development of 1700023E05Rik Inhibitors involves a rigorous process of molecular design, synthesis, and testing. Researchers utilize advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling to understand the three-dimensional structure of the 1700023E05Rik protein. This structural insight is crucial for identifying potential binding sites and for designing inhibitors that can effectively interact with the protein. The interaction between these inhibitors and the 1700023E05Rik protein typically involves the formation of non-covalent bonds, such as hydrogen bonds, ionic interactions, and hydrophobic contacts. These interactions are finely tuned to ensure that the inhibitors can effectively bind to the protein with high specificity, thereby modulating its function.

The chemical synthesis of 1700023E05Rik Inhibitors is a complex process that often requires multiple steps to achieve the desired molecular structure. Synthetic chemists employ a variety of chemical reactions and techniques to construct the inhibitor molecules, carefully optimizing each step to improve yield, purity, and the pharmacokinetic properties of the compounds. Once synthesized, these inhibitors undergo extensive in vitro testing to evaluate their binding affinity, specificity, and the overall effectiveness in interacting with the 1700023E05Rik protein. These studies are essential for understanding the molecular basis of the inhibitor-protein interaction and for further refining the chemical structure of the inhibitors. Through this iterative process of design, synthesis, and testing, 1700023E05Rik Inhibitors are developed with a focus on their molecular interaction with the target protein, providing valuable insights into the complex mechanisms of protein function and interaction in biological systems.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$153.00
$396.00
113
(4)

A potent kinase inhibitor, affecting phosphorylation pathways related to 1700023E05Rik.

Sodium Orthovanadate

13721-39-6sc-3540
sc-3540B
sc-3540A
5 g
10 g
50 g
$49.00
$57.00
$187.00
142
(4)

A phosphatase inhibitor, potentially affecting dephosphorylation processes in pathways where 1700023E05Rik is involved.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

An HDAC inhibitor, possibly affecting gene expression processes related to the activity of 1700023E05Rik.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$90.00
$204.00
13
(1)

An inhibitor of transcription factors, potentially affecting gene regulation pathways where 1700023E05Rik might be involved.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

An mTOR inhibitor, potentially affecting cell growth and proliferation pathways involving 1700023E05Rik.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

A proteasome inhibitor, possibly influencing protein degradation pathways related to 1700023E05Rik.

Nifedipine

21829-25-4sc-3589
sc-3589A
1 g
5 g
$59.00
$173.00
15
(1)

A calcium channel blocker, potentially affecting calcium signaling pathways in which 1700023E05Rik might play a role.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

A PI3K inhibitor, potentially affecting signaling pathways that might involve 1700023E05Rik.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

An inhibitor of the MAPK/ERK pathway, possibly influencing signaling pathways relevant to 1700023E05Rik.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

A PI3K inhibitor, potentially affecting pathways in which 1700023E05Rik may be involved.